Boston, MA

Cancer Medicine
& Hematology

3 - 6 October 2020
The Fairmont Copley Plaza Hotel
Boston, MA

This course has been canceled.
Please see the details below.

Due to the Coronavirus (COVID-19), Dana-Farber/Partners Cancer Care has decided to cancel the October 3 – 6 2020 Cancer Medicine and Hematology course. Please check your email in the coming days with details on future course dates as well as refund processes and options.

For immediate questions, please email Laurie Bertoncini at laurie@calibremeetings.com

Offered By

Dana Farber Partners Cancer Care Dana Farber Partners Cancer Care
Massachusetts General Hospital
Dana Farber Cancer Institute
Brigham and Women's Hospital

Care for patients with solid tumors, hematologic malignancies, and benign hematologic disorders continues to evolve with the development of novel therapeutic agents and testing modalities, accumulation of clinical trial data, and ongoing revisions to expert guidelines.

Oncologists, hematologists, and other clinicians who participate in the care of patients with these disorders are challenged to stay current on the latest diagnosis, treatment, and management advances.

Cancer Medicine and Hematology is an intensive four-day course providing a comprehensive review of the clinical, molecular, and pathophysiologic basis for the diagnosis and treatment of neoplastic diseases and benign hematologic conditions.

Primary emphasis will be placed upon the broad area of medical management within a multidisciplinary environment. Recent advances in molecular genetics, clinical pharmacology, epidemiology, and supportive care will be stressed.

This course will engage participants in lectures using an audience response system as well as interactive panels and case discussions.

Dr Robert Mayer, MD
Course Director
Robert J. Mayer, MD

Learner Objectives

After completion of this course, participants will be able to:

  • Apply recent advances in diagnosis, risk assessment, and disease monitoring to the selection of systemic therapies and overall management approaches for patients with hematologic malignancies, including leukemia, lymphoma, and myeloma
  • Develop evidence-based, multimodal treatment regimens for patients with gastrointestinal cancers, including hereditary cancers, gastroesophageal cancers, colorectal cancers, and pancreatic and hepatobiliary cancers
  • Select individualized treatment approaches for patients with gynecologic cancers that take into account recent clinical data on new therapeutic approaches as well as expert recommended best practices
  • Choose appropriately individualized treatment regimens for patients with lung, head and neck, and thyroid cancers that take into account molecular and clinical characteristics of each patient
  • Assess available clinical evidence to the individualized selection of multimodal treatment approaches for patients with genitourinary cancers, including prostate, bladder, and testicular cancers
  • Apply current evidence-based standards of care to breast cancer in early and advanced treatment settings, including subtype-specific care for HR-positive, HER2-positive, and triple negative disease
  • Develop up-to-date management strategies for a wide range of additional malignancies, including melanoma and other skin cancers, neuroendocrine tumors, central nervous system tumors, and other types of cancers
  • Select optimal management approaches to benign hematologic disorders, incorporating new clinical evidence and new therapies into current practice paradigms

Credit Information

Physician
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CME Outfitters and Dana-Farber Cancer Institute. CME Outfitters is accredited by the ACCME to provide continuing medical education for physicians.

CME Outfitters designates this activity for a maximum of TBD AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to TBD MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

While offering credits noted above, the course is not intended to provide extensive training or certification in the field.

Course schedule

“Excellent comprehensive review and update. I was able to achieve a 360° view on the current status of clinical oncology”
- 2018 Course Attendee

Faculty

“All speakers were excellent. Uniformly excellent. You have nailed down the best of the best.”
- 2018 Course Attendee

Due to the Coronavirus (COVID-19), Dana-Farber/Partners Cancer Care has decided to cancel the October 3 – 6 2020 Cancer Medicine and Hematology course. Please check your email in the coming days with details on future course dates as well as refund processes and options.

For immediate questions, please email Laurie Bertoncini at laurie@calibremeetings.com

© 2020 Cancer Medicine & Hematology. All rights reserved.